| scholarly article | Q13442814 |
| P2093 | author name string | Michihiko Kuwano | |
| Yuji Basaki | |||
| Hidetaka Uramoto | |||
| Hiroto Izumi | |||
| Kimitoshi Kohno | |||
| Masayoshi Kage | |||
| Kazutaka Nakashima | |||
| Akihiko Kawahara | |||
| Mayumi Ono | |||
| Kosei Yasumoto | |||
| Chizuko Yamamoto | |||
| P2860 | cites work | EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib | Q24561953 |
| APE1/Ref-1 regulates PTEN expression mediated by Egr-1 | Q24650473 | ||
| Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain | Q24794765 | ||
| EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Q27824812 | ||
| EGFR mutation and resistance of non-small-cell lung cancer to gefitinib | Q27824829 | ||
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
| Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib | Q27861059 | ||
| KRAS mutations in non-small cell lung cancer | Q28240568 | ||
| PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR | Q28240702 | ||
| One hundred years of lung cancer | Q28257141 | ||
| The biology and clinical relevance of the PTEN tumor suppressor pathway | Q28272157 | ||
| Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways | Q28274882 | ||
| Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers | Q29615475 | ||
| A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization | Q29618351 | ||
| Egr1 transcription factor: multiple roles in prostate tumor cell growth and survival | Q34133497 | ||
| Global cancer statistics in the year 2000. | Q34571897 | ||
| Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer | Q34778936 | ||
| Transcriptional regulation of the Icam-1 gene in antigen receptor- and phorbol ester-stimulated B lymphocytes: role for transcription factor EGR1. | Q36366454 | ||
| Molecular determinants of response to RTK-targeting agents in nonsmall cell lung cancer | Q36430273 | ||
| Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs | Q36692592 | ||
| Why is PTEN an important tumor suppressor? | Q36986667 | ||
| PTEN expression elicited by EGR-1 transcription factor in calyculin A-induced apoptotic cells. | Q38334830 | ||
| Egr-1 activates basic fibroblast growth factor transcription. Mechanistic implications for astrocyte proliferation | Q38354392 | ||
| KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer | Q38432430 | ||
| Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis | Q39710176 | ||
| Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. | Q39916367 | ||
| Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors | Q40251398 | ||
| Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp | Q40384287 | ||
| HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells | Q40421135 | ||
| ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells | Q40657593 | ||
| Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation | Q40732720 | ||
| Basic fibroblast growth factor transcriptional autoregulation requires EGR-1. | Q41110093 | ||
| The reciprocal role of Egr-1 and Sp family proteins in regulation of the PTP1B promoter in response to the p210 Bcr-Abl oncoprotein-tyrosine kinase | Q43584896 | ||
| The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling | Q43848062 | ||
| Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. | Q45190258 | ||
| Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. | Q45933831 | ||
| Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer | Q46051178 | ||
| EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) | Q64135644 | ||
| Transforming growth factor-alpha enhances cyclin D1 transcription through the binding of early growth response protein to a cis-regulatory element in the cyclin D1 promoter | Q73960005 | ||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| antineoplastic resistance | Q13416904 | ||
| P304 | page(s) | 8715-8725 | |
| P577 | publication date | 2010-10-19 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations | |
| Loss of PTEN Expression by Blocking Nuclear Translocation of EGR1 in Gefitinib-Resistant Lung Cancer Cells Harboring Epidermal Growth Factor Receptor–Activating Mutations | |||
| P478 | volume | 70 |
| Q38717620 | A genetic interaction analysis identifies cancer drivers that modify EGFR dependency |
| Q35081010 | Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors. |
| Q38021967 | Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny |
| Q47119773 | Acquisition of EGFR TKI resistance and EMT phenotype is linked with activation of IGF1R/NF-κB pathway in EGFR-mutant NSCLC. |
| Q51072877 | Alteration of the E-cadherin/β-catenin complex predicts poor response to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment. |
| Q33744196 | Antitumor activity of high-dose pulsatile gefitinib in non-small-cell lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors |
| Q37211974 | Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells |
| Q37708873 | BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations |
| Q64297990 | Chemotherapy combined with Endostar as salvage treatment for EGFR-tyrosine kinase inhibitor primary resistance in an advanced non-small cell lung cancer patient with EGFR L858R mutation and ROS1 fusion: A case report |
| Q38504491 | Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance. |
| Q35602423 | Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib |
| Q60947650 | Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients |
| Q38543780 | Current and future molecular diagnostics in non-small-cell lung cancer. |
| Q36834883 | Drug Resistance to EGFR Inhibitors in Lung Cancer |
| Q41122951 | EB-virus latent membrane protein 1 potentiates the stemness of nasopharyngeal carcinoma via preferential activation of PI3K/AKT pathway by a positive feedback loop |
| Q37180302 | EGFR inhibition in non-small cell lung cancer: current evidence and future directions |
| Q37204247 | EGFR protein expression using a specific intracellular domain antibody and PTEN and clinical outcomes in squamous cell lung cancer patients with EGFR-tyrosine kinase inhibitor therapy |
| Q49887890 | EGFR-TKIs resistance via EGFR-independent signaling pathways |
| Q91937535 | EGR1 regulates angiogenic and osteoclastogenic factors in prostate cancer and promotes metastasis |
| Q49497954 | EYA2 promotes lung cancer cell proliferation by downregulating the expression of PTEN. |
| Q37099888 | Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer |
| Q39124519 | Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer |
| Q53689237 | Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3. |
| Q35152542 | Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo |
| Q38966912 | FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor |
| Q35117568 | From the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer |
| Q41708722 | High PHLPP1 expression levels predicts longer time of acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma |
| Q39328532 | JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation |
| Q47754114 | Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells |
| Q26829104 | Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands |
| Q54196176 | LncRNA expression profiles of EGFR exon 19 deletions in lung adenocarcinoma ascertained by using microarray analysis. |
| Q28481370 | Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells |
| Q99589746 | M2 macrophages reduce the effect of gefitinib by activating AKT/mTOR in gefitinib-resistant cell lines HCC827/GR |
| Q47146662 | Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer |
| Q27340255 | Microfluidic enrichment for the single cell analysis of circulating tumor cells |
| Q28484612 | Modeling of tumor progression in NSCLC and intrinsic resistance to TKI in loss of PTEN expression |
| Q53694782 | Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non-small cell lung cancer cells. |
| Q36814305 | Molecular mechanisms contributing to resistance to tyrosine kinase-targeted therapy for non-small cell lung cancer |
| Q27691299 | Molecular pathology of lung cancer: key to personalized medicine |
| Q47130146 | Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms. |
| Q36801144 | Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer |
| Q47590937 | PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway |
| Q34202681 | PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control |
| Q38629644 | PTEN and PI3K/AKT in non-small-cell lung cancer. |
| Q92569890 | PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around |
| Q37706156 | Paradoxical induction of growth arrest and apoptosis by EGF via the up-regulation of PTEN by activating Redox factor-1/Egr-1 in human lung cancer cells |
| Q38697136 | Phosphatase and tensin homolog deleted on chromosome 10 degradation induced by NEDD4 promotes acquired erlotinib resistance in non-small-cell lung cancer |
| Q54979862 | Polyamine-Targeting Gefitinib Prodrug and its Near-Infrared Fluorescent Theranostic Derivative for Monitoring Drug Delivery and Lung Cancer Therapy. |
| Q33684793 | Reduced expression levels of PTEN are associated with decreased sensitivity of HCC827 cells to icotinib |
| Q34704781 | Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors |
| Q91993534 | Research progress on the relationship between lung cancer drug-resistance and microRNAs |
| Q35632411 | Sarcomatous transformation of EGFR and TP53 mutation-positive metastatic adenocarcinoma of the lungs, masquerading as a primary pleomorphic sarcoma of the proximal femur |
| Q34201724 | Sequence-dependent effect of docetaxel with gefitinib on the proliferation and apoptosis of lung adenocarcinoma cell H1975 |
| Q28391425 | Sequential activation of Elk-1/Egr-1/GADD45α by arsenic |
| Q42434753 | Small activating ribonucleic acid reverses tyrosine kinase inhibitor resistance in epidermal growth factor receptor-mutant lung cancer by increasing the expression of phosphatase and tensin homolog |
| Q53707746 | Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: A case report and literatures review. |
| Q36247850 | Subsequent treatment of epidermal growth factor receptor-tyrosine kinase inhibitor failure in patients with advanced lung adenocarcinoma |
| Q27853317 | TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun |
| Q54977358 | Targeting Nicotinamide N-Methyltransferase and miR-449a in EGFR-TKI-Resistant Non-Small-Cell Lung Cancer Cells. |
| Q34852951 | Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells |
| Q42378470 | The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells |
| Q48695556 | The long non-coding RNA, LINC00635-001, sensitizes EGFR-TKI-resistant human lung cancer cells in vitro by inhibiting Akt activation |
| Q50237958 | The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor. |
| Q38390044 | Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients |
| Q39218984 | Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency |
| Q54279044 | [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650]. |
| Q35406639 | miR-205 regulates A549 cells proliferation by targeting PTEN. |
| Q36093612 | miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance. |
| Q42154043 | siRNA targeting of Trop2 suppresses the proliferation and invasion of lung adenocarcinoma H460 cells |
Search more.